Frequency Therapeutics Inc Stock

$12.03

2.51% yesterday

Nasdaq, Jun 27, 10:15 pm CET

ISIN

US35803L1089

Symbol

KRRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Frequency Therapeutics Inc Stock price

$12.03

-1,052.47 98.87% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-0.31 2.51%

ISIN

US35803L1089

Symbol

KRRO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Basic

Market capitalization

$113.0m

Enterprise Value

$-2.0m

Net debt

$-115.0m

Cash

$115.0m

Shares outstanding

9.4m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

23.44 | 30.13

EV/Sales

negative | negative

EV/FCF

0.03

P/B

0.81

Financial Health

Equity Ratio

70.90%

Return on Equity

-52.10%

ROCE

-50.43%

ROIC

-119.77%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$4.8m | $3.7m

EBITDA

$-91.4m | -

EBIT

$-95.5m

Net Income

$-87.4m | $-91.4m

Free Cash Flow

$-75.1m

Growth (TTM | estimate)

Revenue

- | 65.15%

EBITDA

-11.31% | -

EBIT

-11.70%

Net Income

-7.66% | -9.39%

Free Cash Flow

15.09%

Margin (TTM | estimate)

Gross

EBITDA

-1,896.14% | -

EBIT

-1,980.44%

Net

-1,813.13% | -2,438.66%

Free Cash Flow

-1,556.63%

EPS

$-9.31

FCF per Share

$-7.99

Short interest

13.00%

Employees

104.00

Rev per Employee

$20.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Frequency Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Frequency Therapeutics Inc forecast:

15x Buy

94%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Frequency Therapeutics Inc forecast:

Buy

94%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Frequency Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	4.82 4.82	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	31 31	17% 17% 633%
- Research and Development Expense	70 70	17% 17% 1,448%
EBITDA	-91 -91	11% 11% -1,896%
- Depreciation and Amortization	4.06 4.06	21% 21% 84%
EBIT (Operating Income) EBIT	-95 -95	12% 12% -1,981%
Net Profit	-87 -87	8% 8% -1,813%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Frequency Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram Aiyar, Ph.D.

Neutral

GlobeNewsWire

●

about 2 months ago

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2025 and provided a business update.

Neutral

GlobeNewsWire

●

3 months ago

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & Technical Operations and promotion of Oliver Dolan to Principal Accounting Officer Strengthens leadership team with additional key appointment of GaoZhong Zhu, Ph.D. as Senior Vice President of Chemistry, Manufacturing and Controls (CMC) & ...

More Frequency Therapeutics Inc News

Company Profile

Frequency Therapeutics, Inc. engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Its product pipeline include Sensorineural hearing loss (FX-322), and Multiple Sclerosis. The company was founded by Robert S. Langer, Jr., David L. Lucchino, Christopher Loose and Will J. McLean on November 13, 2014 and is headquartered in Woburn, MA.

Head office	United States
CEO	Ram Aiyar
Employees	104
Founded	2018
Website	www.korrobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now